Melanoma arising from pigment-producing cells known as melanocytes is the deadliest form of skin cancer. A major cause of melanoma is excessive exposure to ultraviolet light, from sunlight or other sources, which can trigger mutations that promote tumor formation.
Health Professionals
Study points to a strategy for inhibiting hyper-progression of melanoma
Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
New Algorithm Proposes Targeted Lipase Monitoring for Pancreatic Adverse Events In Melanoma
Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.
Podcast: JCO Article Insights: Nivolumab + Relatlimab v Nivolumab + Ipilimumab in Melanoma
In this JCO Article Insights episode, Rohit Singh provides a summary on “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data", by Long et al, published in the November issue of the Journal of Clinical Oncology. The article provides insights into the use of the two dual immune checkpoint inhibitor regimens in patients with untreated advanced melanoma.